Ascension: Appointment of Ben Vertannes as Head of Global Marketing finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BerGenBio Presents Preclinical COVID-19 Data at Annual Conference on Retroviruses and Opportunistic Infections (CROI 2021)
BERGEN, Norway, March 6, 2021 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021.
The presentation was led by BerGenBio s collaborator, Professor Wendy Maury, Professor of Microbiology and Immunology at the University of Iowa (Iowa City, USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to infect cell lines from the human airway, increasing the amount of virus measured in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces th
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV .
Hyloris PharmaceuticalsMarch 5, 2021 GMT
Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets
Footprint across Europe now extended to a total of 20 EU member states
Maxigesic® IV offers a non-opioid alternative in post-operative pain management
Liège, Belgium – 5 March 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner AFT Pharmaceuticals (“AFT”) has signed an exclusive licensing agreement with Aguettant for Maxigesic IV, a novel, dual mode-of-action non-opioid pain treatment delivered through intravenous (IV) infusion, in eight Euro
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U S Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.